GM

DIETARY_SUPPLEMENT2 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital, Gonzalo Jorquera, PhD

Conditions

Insulin Resistance SyndromeNeurotoxicityObesity & OverweightOverweight (BMI > 25)Type 2 Diabetes

Phase 3

Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer

CompletedNCT02486198

Tianjin Medical University Cancer Institute and HospitalNeurotoxicity

Start: 2015-05-05End: 2018-02-02Updated: 2018-02-05

Unknown Phase

Gummy Candies With Maqui Berry

CompletedNCT07373795

Gonzalo Jorquera, PhDInsulin Resistance Syndrome, Obesity & Overweight, Overweight (BMI > 25) +1

Start: 2025-12-02End: 2026-01-13Updated: 2026-01-28

Related Papers

Monosialotetrahexosylganglioside in the treatment of chronic oxaliplatin-induced peripheral neurotoxicity: TJMUCH-GI-001, a randomised controlled trial.

2021-10-294 citations

Survival and safety of monosialotetrahexosylganglioside in GI cancer patients with oxaliplatin-induced peripheral neurotoxicity-result from TJMUCH-GI-001 trial.

Journal of Clinical Oncology2019-05-20

Randomized, double-blind, phase III trial of monosialotetrahexosylganglioside versus placebo in GI cancer patients with oxaliplatin induced peripheral neurotoxicity (TJMUCH-GI-001).

Journal of Clinical Oncology2018-05-201 citations